Company: NYXH
Filing Date: 2025-08-11
Form Type: 6-K
Source: 0001104659-25-075831
Chunk: 3

Company: Nyxoah SA
Filing Date: 2025-08-11
Form: 6-K
Chunk 3
---
 from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this Report or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Report.

Risk Factors

Risks Related to Our Business

We have been and could become subject to intellectual property litigation.

The medical device industry is characterized by
rapidly changing products and technologies and there is intense competition to establish intellectual property and proprietary rights
covering the use of these new products and the related technologies. This vigorous pursuit of intellectual property and proprietary rights
has resulted and will continue to result in extensive litigation and administrative proceedings over patent and other intellectual property
rights. Whether a product and/or a process infringes a patent involves complex legal and factual issues, and the outcome of such disputes
is often uncertain.

There may be existing patents of which we are
unaware that are inadvertently infringed by the Genio system. We cannot guarantee that any of our patent searches or analyses, including
the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor
can we be certain that we have identified each and every third-party patent and pending patent application in the United States and abroad
that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. Patent applications in the United
States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest
filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates could have
been filed by third parties without our knowledge. Additionally, pending patent applications that have been published can, subject to
certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope
of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution
history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively
impact our ability to market our product candidates.

We may incorrectly determine that our product
candidates are not covered by a third-party patent or may incorrectly predict whether a third party’s pending application will issue
with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider
relevant may be incorrect, which may negatively impact our ability to develop and market